Lexicon Pharmaceuticals, Inc. (LXRX)

Over the past six months, Lexicon Pharmaceuticals, Inc. experienced several stock-impacting events. In January 2026, a business and pipeline update at the J.P. Morgan Healthcare Conference triggered a $10 million milestone payment for LX9851. December 2025 saw the publication of preclinical data on Acyl-CoA Synthetase 5 (ACSL5) and clinical data on sotagliflozin's effect on adipose distribution. In November 2025, the company presented at the Jefferies London Healthcare Conference and reported new sotagliflozin clinical data and Q3 2025 earnings. September 2025 included presentations on preclinical data for pilavapadin and insights from a study on diabetic peripheral neuropathic pain. August 2025 marked the scheduled release of Q2 2025 financial results. May 2025 saw Lexicon reporting a Q1 2025 loss per share that beat estimates, but revenue missed expectations. In March 2025, Q4 2024 financial results were reported, highlighting progress in clinical development programs. The share price as of January 8, 2026, was $1.18, a 54.01% increase from January 10, 2025.

Information specifically detailing the demand seasonality for Lexicon Pharmaceuticals, Inc.'s products and services is not readily available.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products for human diseases, particularly in areas like diabetes, cardiovascular diseases, and rare diseases. Its key products include INPEFA (sotagliflozin), approved for reducing cardiovascular risks in adults with heart failure or type 2 diabetes, and LX9211, in Phase II clinical development for neuropathic pain. LX9851, a drug candidate for obesity and weight management, is in preclinical development under a licensing agreement with Novo Nordisk.

Lexicon Pharmaceuticals, Inc. has its corporate headquarters and primary research facility in The Woodlands, Texas, where its drug target discovery, validation, preclinical research, clinical development, and regulatory team are based. Additionally, the company has a campus in Princeton, New Jersey, dedicated to small molecule medicinal chemistry and preclinical development efforts.

In the past year, Lexicon Pharmaceuticals has focused on increasing investor visibility and scientific validation through participation in healthcare investor conferences and publishing preclinical and clinical data. These activities aim to maintain a positive reputation within the scientific and investment communities by demonstrating progress and potential in its pipeline.

Lexicon Pharmaceuticals, Inc. has a mixed ownership structure, with approximately 72.07% of its stock held by institutional investors and about 1.17% by insiders. Major institutional owners include Artal Group S.A., Siren, L.L.C., Fmr Llc, Vanguard Group Inc, Millennium Management Llc, BlackRock, Inc., Sessa Capital IM, L.P., Citadel Advisors Llc, CIBC Private Wealth Group Llc, and Geode Capital Management, Llc. Raymond Debbane owns the most shares among individual investors.